{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:07:00Z","timestamp":1784304420961,"version":"3.55.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-025-01145-6","type":"journal-article","created":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T03:16:59Z","timestamp":1748056619000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["RETRACTED ARTICLE: Comparing Moderna\u2019s mRNA-1083 and Pfizer\u2019s dual-target mRNA vaccines for influenza and COVID-19"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7245-0340","authenticated-orcid":false,"given":"Adewunmi","family":"Akingbola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9478-5360","authenticated-orcid":false,"given":"Abiodun","family":"Adegbesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1509-0274","authenticated-orcid":false,"given":"Kolade","family":"Adegoke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5938-4817","authenticated-orcid":false,"given":"Courage","family":"Idahor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Mariaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Favour","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1877-8205","authenticated-orcid":false,"given":"Raolat Adenike","family":"Salami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olajide","family":"Ojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Nwaeze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1241-4301","authenticated-orcid":false,"given":"Owolabi","family":"Abdullahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Chuku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,24]]},"reference":[{"key":"1145_CR1","unstructured":"Global Influenza Programme [Internet]. [cited 2025 Jan 2]. Available from: https:\/\/www.who.int\/teams\/global-influenza-programme\/surveillance-and-monitoring\/burden-of-disease."},{"key":"1145_CR2","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.gheart.2014.08.004","volume":"9","author":"WA Fischer","year":"2014","unstructured":"Fischer, W. A., Gong, M., Bhagwanjee, S. & Sevransky, J. Global burden of influenza as a cause of cardiopulmonary morbidity and mortality. Glob. Heart 9, 325\u2013336 (2014).","journal-title":"Glob. Heart"},{"key":"1145_CR3","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/S0140-6736(17)33293-2","volume":"391","author":"AD Iuliano","year":"2018","unstructured":"Iuliano, A. D. et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet 391, 1285\u20131300 (2018).","journal-title":"Lancet"},{"key":"1145_CR4","unstructured":"Influenza (Seasonal) [Internet]. [cited 2025 Jan 2]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/influenza-(seasonal)."},{"key":"1145_CR5","unstructured":"Influenza (Flu) | Influenza (Flu) | CDC [Internet]. [cited 2025 Jan 2]. Available from: https:\/\/www.cdc.gov\/flu\/index.html."},{"key":"1145_CR6","doi-asserted-by":"publisher","first-page":"C8","DOI":"10.1016\/j.vaccine.2008.04.011","volume":"26","author":"MF Boni","year":"2008","unstructured":"Boni, M. F. Vaccination and antigenic drift in influenza. Vaccine 26, C8\u2013C14 (2008).","journal-title":"Vaccine"},{"key":"1145_CR7","first-page":"46","volume":"79","author":"C McCaughey","year":"2010","unstructured":"McCaughey, C. Influenza: a virus of our times. Ulst. Med J. 79, 46\u201351 (2010).","journal-title":"Ulst. Med J."},{"key":"1145_CR8","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu, N. et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N. Engl. J. Med 382, 727\u2013733 (2020).","journal-title":"N. Engl. J. Med"},{"key":"1145_CR9","unstructured":"datadot [Internet]. [cited 2025 Jan 2]. COVID-19 cases | WHO COVID-19 dashboard. Available from: https:\/\/data.who.int\/dashboards\/covid19\/cases"},{"key":"1145_CR10","doi-asserted-by":"publisher","unstructured":"Aerodynamic Characteristics and RNA Concentration of SARS-CoV-2 Aerosol in Wuhan Hospitals during COVID-19 Outbreak | bioRxiv [Internet]. [cited 2025 Jan 2]. Available from: https:\/\/doi.org\/10.1101\/2020.03.08.982637v1","DOI":"10.1101\/2020.03.08.982637v1"},{"key":"1145_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.681469","volume":"8","author":"M Dadashi","year":"2021","unstructured":"Dadashi, M. et al. COVID-19 and Influenza Co-infection: A Systematic Review and Meta-Analysis. Front Med (Lausanne) 8, 681469 (2021).","journal-title":"Front Med (Lausanne)"},{"key":"1145_CR12","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1093\/ije\/dyab081","volume":"50","author":"J Stowe","year":"2021","unstructured":"Stowe, J. et al. Interactions between SARS-CoV-2 and influenza, and the impact of coinfection on disease severity: a test-negative design. Int J. Epidemiol. 50, 1124\u20131133 (2021).","journal-title":"Int J. Epidemiol."},{"key":"1145_CR13","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41422-021-00473-1","volume":"31","author":"L Bai","year":"2021","unstructured":"Bai, L. et al. Coinfection with influenza A virus enhances SARS-CoV-2 infectivity. Cell Res 31, 395\u2013403 (2021).","journal-title":"Cell Res"},{"key":"1145_CR14","doi-asserted-by":"publisher","first-page":"20786","DOI":"10.1073\/pnas.1909613116","volume":"116","author":"P Sah","year":"2019","unstructured":"Sah, P. et al. Future epidemiological and economic impacts of universal influenza vaccines. Proc. Natl Acad. Sci. USA 116, 20786\u201320792 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1145_CR15","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","volume":"20","author":"N Chaudhary","year":"2021","unstructured":"Chaudhary, N., Weissman, D. & Whitehead, K. A. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat. Rev. Drug Discov. 20, 817\u2013838 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1145_CR16","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/274923a0","volume":"274","author":"GJ Dimitriadis","year":"1978","unstructured":"Dimitriadis, G. J. Translation of rabbit globin mRNA introduced by liposomes into mouse lymphocytes. Nature 274, 923\u2013924 (1978).","journal-title":"Nature"},{"key":"1145_CR17","doi-asserted-by":"publisher","first-page":"6077","DOI":"10.1073\/pnas.86.16.6077","volume":"86","author":"RW Malone","year":"1989","unstructured":"Malone, R. W., Felgner, P. L. & Verma, I. M. Cationic liposome-mediated RNA transfection. Proc. Natl Acad. Sci. USA 86, 6077\u20136081 (1989).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1145_CR18","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1126\/science.1690918","volume":"247","author":"JA Wolff","year":"1990","unstructured":"Wolff, J. A. et al. Direct gene transfer into mouse muscle in vivo. Science 247, 1465\u20131468 (1990).","journal-title":"Science"},{"key":"1145_CR19","first-page":"111","volume":"440","author":"MG Alameh","year":"2022","unstructured":"Alameh, M. G., Weissman, D. & Pardi, N. Messenger RNA-Based Vaccines Against Infectious Diseases. Curr. Top. Microbiol Immunol. 440, 111\u2013145 (2022).","journal-title":"Curr. Top. Microbiol Immunol."},{"key":"1145_CR20","first-page":"1397","volume":"55","author":"RM Conry","year":"1995","unstructured":"Conry, R. M. et al. Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Res 55, 1397\u20131400 (1995).","journal-title":"Cancer Res"},{"key":"1145_CR21","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","volume":"23","author":"K Karik\u00f3","year":"2005","unstructured":"Karik\u00f3, K., Buckstein, M., Ni, H. & Weissman, D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23, 165\u2013175 (2005).","journal-title":"Immunity"},{"key":"1145_CR22","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.omtn.2019.02.018","volume":"150","author":"M Baiersd\u00f6rfer","year":"2019","unstructured":"Baiersd\u00f6rfer, M. et al. A Facile Method for the Removal of dsRNA Contaminant from In Vitro-Transcribed mRNA. Mol. Ther. Nucleic Acids 150, 26\u201335 (2019).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1145_CR23","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.2147\/IDR.S315727","volume":"14","author":"MT Mascellino","year":"2021","unstructured":"Mascellino, M. T., Di Timoteo, F., De Angelis, M. & Oliva, A. Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety. Infect. Drug Resist 14, 3459\u20133476 (2021).","journal-title":"Infect. Drug Resist"},{"key":"1145_CR24","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.molmed.2013.09.002","volume":"19","author":"C Pollard","year":"2013","unstructured":"Pollard, C., De Koker, S., Saelens, X., Vanham, G. & Grooten, J. Challenges and advances towards the rational design of mRNA vaccines. Trends Mol. Med 19, 705\u2013713 (2013).","journal-title":"Trends Mol. Med"},{"key":"1145_CR25","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.ymthe.2019.01.020","volume":"27","author":"G Maruggi","year":"2019","unstructured":"Maruggi, G., Zhang, C., Li, J., Ulmer, J. B. & Yu, D. mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases. Mol. Ther. 27, 757\u2013772 (2019).","journal-title":"Mol. Ther."},{"key":"1145_CR26","doi-asserted-by":"publisher","first-page":"3860","DOI":"10.3390\/cancers14163860","volume":"14","author":"J Wesolowski","year":"2022","unstructured":"Wesolowski, J., Tankiewicz-Kwedlo, A. & Pawlak, D. Modern Immunotherapy in the Treatment of Triple-Negative Breast Cancer. Cancers (Basel) 14, 3860 (2022).","journal-title":"Cancers (Basel)"},{"key":"1145_CR27","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41577-019-0243-3","volume":"20","author":"JR Mascola","year":"2020","unstructured":"Mascola, J. R. & Fauci, A. S. Novel vaccine technologies for the 21st century. Nat. Rev. Immunol. 20, 87\u201388 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"1145_CR28","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.7150\/ijbs.59233","volume":"17","author":"JW Park","year":"2021","unstructured":"Park, J. W., Lagniton, P. N. P., Liu, Y. & Xu, R. H. mRNA vaccines for COVID-19: what, why and how. Int J. Biol. Sci. 17, 1446\u20131460 (2021).","journal-title":"Int J. Biol. Sci."},{"key":"1145_CR29","unstructured":"Pfizer and BioNTech Initiate Phase 1 Study of Single Dose mRNA-Based Combination Vaccine Candidate for Influenza and COVID-19 | Pfizer [Internet]. [cited 2025 Jan 2]. Available from: https:\/\/www.pfizer.com\/news\/announcements\/pfizer-and-biontech-initiate-phase-1-study-single-dose-mrna-based-combination"},{"key":"1145_CR30","unstructured":"Moderna Announces Positive Phase 1\/2 Data from mRNA-1083, the Company\u2019s Combination Vaccine Against Influenza and COVID-19 [Internet]. [cited 2025 Jan 2]. Available from: https:\/\/investors.modernatx.com\/news\/news-details\/2023\/Moderna-Announces-Positive-Phase-12-Data-from-mRNA-1083-the-Companys-Combination-Vaccine-Against-Influenza-and-COVID-19\/default.aspx"},{"key":"1145_CR31","unstructured":"Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19 | Pfizer [Internet]. [cited 2025 Jan 2]. Available from: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-and-biontech-announce-positive-topline-data-mrna"},{"key":"1145_CR32","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1016\/j.scib.2022.05.018","volume":"67","author":"J Chen","year":"2022","unstructured":"Chen, J. et al. A live attenuated virus-based intranasal COVID-19 vaccine provides rapid, prolonged, and broad protection against SARS-CoV-2. Sci. Bull. (Beijing) 67, 1372\u20131387 (2022).","journal-title":"Sci. Bull. (Beijing)"},{"key":"1145_CR33","doi-asserted-by":"publisher","unstructured":"Wang, Y. et al. Towards broad-spectrum protection: the development and challenges of combined respiratory virus vaccines. Front Cell Infect Microbiol [Internet]. 2024 Jun 5 [cited 2025 Jan 2];14. Available from: https:\/\/doi.org\/10.3389\/fcimb.2024.1412478\/full","DOI":"10.3389\/fcimb.2024.1412478\/full"},{"key":"1145_CR34","doi-asserted-by":"crossref","unstructured":"Wang, Y. et al. Seroprevalence of Avian Influenza A(H5N6) Virus Infection, Guangdong Province, China, 2022 - Volume 30, Number 4\u2014April 2024 - Emerging Infectious Diseases journal - CDC. [cited 2025 Jan 2]; Available from: https:\/\/wwwnc.cdc.gov\/eid\/article\/30\/4\/23-1226_article","DOI":"10.3201\/eid3004.231226"},{"key":"1145_CR35","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.chom.2022.11.016","volume":"31","author":"DM Morens","year":"2023","unstructured":"Morens, D. M., Taubenberger, J. K. & Fauci, A. S. Rethinking next-generation vaccines for coronaviruses, influenzaviruses, and other respiratory viruses. Cell Host Microbe 31, 146\u2013157 (2023).","journal-title":"Cell Host Microbe"},{"key":"1145_CR36","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.vaccine.2021.11.097","volume":"40","author":"RP Lennon","year":"2022","unstructured":"Lennon, R. P., Block, R., Schneider, E. C., Zephrin, L. & Shah, A. African American Research Collaborative 2021 COVID Group. Electronic address: henry@africanamericanresearch.us. Underserved population acceptance of combination influenza-COVID-19 booster vaccines. Vaccine 40, 562\u2013567 (2022).","journal-title":"Vaccine"},{"key":"1145_CR37","unstructured":"Encouraging Results Emerge from Phase 1\/2 Study of mRNA-Based Influenza and COVID-19 Combo Vaccines [Internet]. [cited 2025 Jan 2]. Available from: https:\/\/www.infectioncontroltoday.com\/view\/encouraging-results-emerge-from-phase-1-2-study-of-mrna-based-influenza-and-covid-19-combo-vaccines"},{"key":"1145_CR38","unstructured":"Moderna Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19 [Internet]. [cited 2025 Jan 2]. Available from: https:\/\/investors.modernatx.com\/news\/news-details\/2024\/Moderna-Announces-Positive-Phase-3-Data-for-Combination-Vaccine-Against-Influenza-and-COVID-19-\/default.aspx"},{"key":"1145_CR39","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.3390\/vaccines11121737","volume":"11","author":"R Okuyama","year":"2023","unstructured":"Okuyama, R. mRNA and Adenoviral Vector Vaccine Platforms Utilized in COVID-19 Vaccines: Technologies, Ecosystem, and Future Directions. Vaccines (Basel) 11, 1737 (2023).","journal-title":"Vaccines (Basel)"},{"key":"1145_CR40","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12985-024-02350-w","volume":"21","author":"E Stepanova","year":"2024","unstructured":"Stepanova, E. et al. Expression of the SARS-CoV-2 receptor-binding domain by live attenuated influenza vaccine virus as a strategy for designing a bivalent vaccine against COVID-19 and influenza. Virol. J. 21, 82 (2024).","journal-title":"Virol. J."},{"key":"1145_CR41","unstructured":"Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age | Pfizer [Internet]. [cited 2025 Jan 2]. Available from: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-and-biontech-provide-update-mrna-based-combination"},{"key":"1145_CR42","unstructured":"Concurrent Administration of COVID-19 and Influenza Vaccines Enhances Spike-Specific Antibody Responses - PubMed [Internet]. [cited 2025 Jan 2]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/38567194\/"},{"key":"1145_CR43","doi-asserted-by":"crossref","unstructured":"McKernan, K., Helbert, Y., Kane, L. T. & McLaughlin, S. Sequencing of bivalent Moderna and Pfizer mRNA vaccines reveals nanogram to microgram quantities of expression vector dsDNA per dose [Internet]. OSF; 2023 [cited 2025 Jan 2]. Available from: https:\/\/osf.io\/b9t7m","DOI":"10.31219\/osf.io\/b9t7m"},{"key":"1145_CR44","unstructured":"Comparative effectiveness of mRNA-1273 and BNT162b2 COVID-19 vaccines in immunocompromised individuals: a systematic review and meta-analysis using the GRADE framework - PubMed [Internet]. [cited 2025 Jan 2]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37771594\/"},{"key":"1145_CR45","unstructured":"Patient Care Online [Internet]. 2023 [cited 2025 Jan 2]. Moderna Investigational Dual Flu\/COVID-19 Vaccine Shows Positive Phase 1\/2 Results. Available from: https:\/\/www.patientcareonline.com\/view\/moderna-investigational-dual-flu-covid-19-vaccine-shows-positive-phase-1-2-results"},{"key":"1145_CR46","unstructured":"Moderna Expands the Field of mRNA Medicine with Positive Clinical Results Across Cancer, Rare Disease, and Infectious Disease [Internet]. [cited 2025 Jan 2]. Available from: https:\/\/investors.modernatx.com\/news\/news-details\/2023\/Moderna-Expands-the-Field-of-mRNA-Medicine-with-Positive-Clinical-Results-Across-Cancer-Rare-Disease-and-Infectious-Disease\/default.aspx"},{"key":"1145_CR47","unstructured":"Operational guidance on establishing an ultra-cold chain system in support of the Pfizer-BioNTech COVID-19 vaccine rollout, 1 February 2022 [Internet]. [cited 2025 Jan 2]. Available from: https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-UCC_systems-Pfizer-BioNTech_vaccine-2022.1"},{"key":"1145_CR48","unstructured":"Lipid Nanoparticle Delivery Systems to Enable mRNA-Based Therapeutics - PubMed [Internet]. [cited 2025 Jan 2]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35214130\/"},{"key":"1145_CR49","unstructured":"Real-World Evidence Confirms High Effectiveness of Pfizer-BioNTech COVID-19 Vaccine and Profound Public Health Impact of Vaccination One Year After Pandemic Declared | BioNTech [Internet]. [cited 2025 Jan 2]. Available from: https:\/\/investors.biontech.de\/news-releases\/news-release-details\/real-world-evidence-confirms-high-effectiveness-pfizer-biontech"},{"key":"1145_CR50","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.3390\/vaccines9101082","volume":"9","author":"S Wang","year":"2021","unstructured":"Wang, S. et al. COVID-19 Animal Models and Vaccines: Current Landscape and Future Prospects. Vaccines (Basel) 9, 1082 (2021).","journal-title":"Vaccines (Basel)"},{"key":"1145_CR51","unstructured":"Moderna reports promising findings for flu-COVID combo vaccine | CIDRAP [Internet]. [cited 2025 Jan 2]. Available from: https:\/\/www.cidrap.umn.edu\/covid-19\/moderna-reports-promising-findings-flu-covid-combo-vaccine"},{"key":"1145_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00900-5","volume":"9","author":"K Lemdani","year":"2024","unstructured":"Lemdani, K. et al. Distinct dynamics of mRNA LNPs in mice and nonhuman primates revealed by in vivo imaging. NPJ Vaccines 9, 113 (2024).","journal-title":"NPJ Vaccines"},{"key":"1145_CR53","unstructured":"Advances in Development of mRNA-Based Therapeutics - PubMed [Internet]. [cited 2025 Jan 2]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32683507\/"},{"key":"1145_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.729837","volume":"12","author":"E Gabitzsch","year":"2021","unstructured":"Gabitzsch, E. et al. Dual-Antigen COVID-19 Vaccine Subcutaneous Prime Delivery With Oral Boosts Protects NHP Against SARS-CoV-2 Challenge. Front Immunol. 12, 729837 (2021).","journal-title":"Front Immunol."},{"key":"1145_CR55","unstructured":"An imidazole modified lipid confers enhanced mRNA-LNP stability and strong immunization properties in mice and non-human primates - ScienceDirect [Internet]. [cited 2025 Jan 2]. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0142961222002101"},{"key":"1145_CR56","unstructured":"Moderna announces positive Phase III data for Covid-19\/Influenza mRNA vaccine - Clinical Trials Arena [Internet]. [cited 2025 Jan 2]. Available from: https:\/\/www.clinicaltrialsarena.com\/analyst-comment\/moderna-positive-phase-iii-data-covid-19-influenza-mrna-vaccine\/"},{"key":"1145_CR57","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med"},{"key":"1145_CR58","doi-asserted-by":"crossref","unstructured":"Cascini, F., Pantovic, A., Al-Ajlouni, Y., Failla, G. & Ricciardi, W. Attitudes, acceptance and hesitancy among the general population worldwide to receive the COVID-19 vaccines and their contributing factors: A systematic review. EClin. Med. 40,101113 (2021).","DOI":"10.1016\/j.eclinm.2021.101113"},{"key":"1145_CR59","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/vaccines11010016","volume":"11","author":"N Tzenios","year":"2022","unstructured":"Tzenios, N., Tazanios, M. E. & Chahine, M. Combining Influenza and COVID-19 Booster Vaccination Strategy to Improve Vaccination Uptake Necessary for Managing the Health Pandemic: A Systematic Review and Meta-Analysis. Vaccines (Basel) 11, 16 (2022).","journal-title":"Vaccines (Basel)"},{"key":"1145_CR60","doi-asserted-by":"crossref","unstructured":"COVID-19 and Seasonal Influenza Vaccination: Cross-Protection, Co-Administration, Combination Vaccines, and Hesitancy [Internet]. [cited 2025 Jan 2]. Available from: https:\/\/www.mdpi.com\/1424-8247\/15\/3\/322","DOI":"10.3390\/ph15030322"},{"key":"1145_CR61","unstructured":"Association between combination COVID-19-influenza vaccination and long COVID in middle-aged and older Europeans: A cross-sectional study - PubMed [Internet]. [cited 2025 Jan 2]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/38724010\/"},{"key":"1145_CR62","unstructured":"Acceptance of Seasonal Influenza Vaccine Following COVID-19 Vaccination: A Survey among Israel Defense Forces Soldiers - PubMed [Internet]. [cited 2025 Jan 2]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36073723\/"},{"key":"1145_CR63","unstructured":"COVID-19 vaccination field guide: 12 strategies for your community. [cited 2025 Jan 2]; Available from: https:\/\/stacks.cdc.gov\/view\/cdc\/123092"},{"key":"1145_CR64","unstructured":"CDC. Centers for Disease Control and Prevention. 2022 [cited 2025 Jan 2]. 12 COVID-19 Vaccination Strategies for Your Community. Available from: https:\/\/archive.cdc.gov\/www_cdc_gov\/vaccines\/covid-19\/vaccinate-with-confidence\/community.html"},{"key":"1145_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-022-00950-y","volume":"7","author":"E Fang","year":"2022","unstructured":"Fang, E. et al. Advances in COVID-19 mRNA vaccine development. Sig Transduct. Target Ther. 7, 1\u201331 (2022).","journal-title":"Sig Transduct. Target Ther."},{"key":"1145_CR66","first-page":"167","volume":"440","author":"A August","year":"2022","unstructured":"August, A., Brito, L., Paris, R. & Zaks, T. Clinical Development of mRNA Vaccines: Challenges and Opportunities. Curr. Top. Microbiol Immunol. 440, 167\u2013186 (2022).","journal-title":"Curr. Top. Microbiol Immunol."},{"key":"1145_CR67","first-page":"28","volume":"12","author":"LVS Kutikuppala","year":"2024","unstructured":"Kutikuppala, L. V. S., Kourampi, I., Kanagala, R. S. D., Bhattacharjee, P. & Boppana, S. H. Prospects and Challenges in Developing mRNA Vaccines for Infectious Diseases and Oncogenic Viruses. Med Sci. (Basel) 12, 28 (2024).","journal-title":"Med Sci. (Basel)"},{"key":"1145_CR68","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.3390\/v15081760","volume":"15","author":"W Zhou","year":"2023","unstructured":"Zhou, W. et al. Vaccines\u2019 New Era-RNA Vaccine. Viruses 15, 1760 (2023).","journal-title":"Viruses"},{"key":"1145_CR69","unstructured":"Eisenman, D. Advarra. 2022 [cited 2025 Jan 2]. mRNA Clinical Trials: Key Regulatory Considerations. Available from: https:\/\/www.advarra.com\/blog\/mrna-clinical-trials-key-regulatory-considerations\/"},{"key":"1145_CR70","unstructured":"Federal Register:: Final Action Under the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (NIH Guidelines) [Internet]. [cited 2025 Jan 2]. Available from: https:\/\/www.federalregister.gov\/documents\/2024\/04\/05\/2024-07082\/final-action-under-the-nih-guidelines-for-research-involving-recombinant-or-synthetic-nucleic-acid"},{"key":"1145_CR71","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","volume":"385","author":"N Barda","year":"2021","unstructured":"Barda, N. et al. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N. Engl. J. Med 385, 1078\u20131090 (2021).","journal-title":"N. Engl. J. Med"},{"key":"1145_CR72","doi-asserted-by":"publisher","first-page":"e668","DOI":"10.1093\/infdis\/jiae114","volume":"230","author":"C Fierro","year":"2024","unstructured":"Fierro, C. et al. Safety and Immunogenicity of a Messenger RNA-Based Cytomegalovirus Vaccine in Healthy Adults: Results From a Phase 1 Randomized Clinical Trial. J. Infect. Dis. 230, e668\u2013e678 (2024).","journal-title":"J. Infect. Dis."}],"updated-by":[{"DOI":"10.1038\/s41541-025-01353-0","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000}}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01145-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01145-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01145-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T20:02:17Z","timestamp":1766606537000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01145-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,24]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1145"],"URL":"https:\/\/doi.org\/10.1038\/s41541-025-01145-6","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,24]]},"assertion":[{"value":"15 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been retracted. Please see the Retraction Notice for more detail:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41541-025-01353-0","URL":"https:\/\/doi.org\/10.1038\/s41541-025-01353-0","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"105"}}